Abridge is expanding from an ambient AI scribe into billing and clinical trial screening, backed by an Eli Lilly equity investment and a new NVIDIA-co-developed clinical foundation model.
Artera's ArteraAI Breast, cleared by the FDA on May 6, 2026, generates a metastasis risk score directly from biopsy slides without requiring additional genomic tissue testing.
GE HealthCare completed a $2.3 billion cash acquisition of Intelerad, a Montreal imaging-software company that manages over 230 million exams a year, betting outpatient imaging data and AI distribution matter more than scanner hardware alone.
Xaira Therapeutics unveiled X-Cell, a virtual-cell AI model trained on the largest genome-wide perturbation dataset ever built, then pivoted from secrecy to hiring dealmakers for pharma partnerships.
The Miami startup building a ChatGPT for physicians raised $250 million in January 2026, doubling its valuation to $12 billion in a year — and it may soon raise again at $20 billion.
A Harvard and Beth Israel Deaconess study published in Science on April 30, 2026 found OpenAI's o1 model beat physicians in six diagnostic experiments, correctly diagnosing 78% of textbook cases versus 30% for doctors.
The FDA's list of authorized AI medical devices topped 1,357 entries in January 2026, and 77 percent of them are radiology tools—revealing both AI's biggest healthcare win and its biggest gaps.
Advocate Health's AI imaging rollout across 22 sites in Wisconsin and North Carolina has expanded from spotting pulmonary embolisms to catching rib fractures, aortic dissections, and brain aneurysms.
Kintsugi, a startup that spent seven years and 30 million dollars building AI that detects depression from voice recordings, shut down in February 2026 after failing to win FDA clearance in time, offering a sobering lesson for AI psychiatric diagnostics.
Mount Sinai scientists found a druggable pocket on a cancer-related protein that AlphaFold2, AlphaFold3, Boltz-2 and molecular dynamics all missed, exposing a structural blind spot in AI-driven drug discovery.